Entero Therapeutics (FRA:366) Total Stockholders Equity : €71.64 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Entero Therapeutics Total Stockholders Equity?

Entero Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €71.64 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Entero Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was €7.35. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Entero Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.09.

Entero Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Entero Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entero Therapeutics Total Stockholders Equity Chart

Entero Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

4.16

-2.17

-6.92

2.59

3.30

Entero Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															2.53	0.81	3.07	3.30	71.64

Entero Therapeutics (FRA:366) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Entero Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(71.635	-	56.747)	/	2.02521
	=	7.35

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Entero Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.421	+	6.003)	/	71.635
	=	0.09

Entero Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Entero Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Entero Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entero Therapeutics Inc (FRA:366) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ENTO:USA

Address

777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431

Website

https://www.firstwavebio.com

First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.

Entero Therapeutics Headlines

No Headlines